The treatment of patients with CARD9 deficiency is empirical, mainly based on antifungal therapies (e.g., azole agents, echinocandins) and on the surgical removal of fungal masses. Here, CARD9 is linked to hyperinsulinemic hypoglycemia, familial, 4.